Search

Displaying results 7211 - 7220 of 10000 in total
  1. Drug

    Dalcetrapib

    go.drugbank.com/drugs/DB12181
    Investigational

    Dalcetrapib is under investigation for the treatment of Acute Coronary Syndrome.

  2. Drug

    VP-14637

    go.drugbank.com/drugs/DB12195
    Investigational

    MDT-637 has been investigated for the treatment of Drug Safety.

  3. Drug

    Tozadenant

    go.drugbank.com/drugs/DB12203
    Investigational

    Tozadenant has been investigated for the basic science of Cocaine Dependence.

  4. Drug

    Anrukinzumab

    go.drugbank.com/drugs/DB12294
    Investigational

    Anrukinzumab has been used in trials studying the diagnostic of Asthma.

  5. Drug

    E7107

    go.drugbank.com/drugs/DB12508
    Investigational

    E7107 has been used in trials studying the treatment of Cancer.

  6. Drug

    N-acetylmannosamine

    go.drugbank.com/drugs/DB12536
    Investigational

    N-acetylmannosamine is under investigation for the other of GNE Myopathy.

  7. Drug

    Spiradoline

    go.drugbank.com/drugs/DB12704
    Investigational

    Spiradoline has been investigated for the basic science of Bipolar Depression.

  8. Drug

    Sisomicin

    go.drugbank.com/drugs/DB12604
    Investigational

    Sisomicin has been used in trials studying the treatment of Pyoderma.

    Synonyms: (2S-CIS)-4-O-(3-AMINO-6-(AMINOMETHYL)-3,4-DIHYDRO-2H-PYRAN-2-YL)-2-DEOXY-6-O-(3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA.-L-ARABINOPYRANOSYL)-D-STREPTAMINE, 2-DEOXY-4-O-(3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA.-L-ARABINOPYRANOSYL)-6-O-(2,6-DIAMINO-2,3,4,6-TETRADEOXY-.ALPHA.-D-GLYCERO-HEX-4-ENOPYRANOSYL)-L-STREPTAMINE
  9. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    [L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906 … The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination

  10. Drug

    ND1251

    go.drugbank.com/drugs/DB05132
    Experimental

    ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression.